Seattle Genetics CEO Clay Siegall has big plans for the company. To implement over 12 new drug patents and add over 100 employees to their workforce. Siegall’s company has manufactured pharmaceuticals for many different diseases, but cancer is its primary focus with its best seller being Adcetris. But now Siegall wants to explore the use and sale of 33A, a pharmaceutical that is undergoing clinical tests at the moment, but is being worked on to treat forms of Lukemia. The company also plans to add drugs for treating breast and bladder cancers, and the new employees will be coming to the company production centers both in the US and Switzerland.
Dr. Clay Siegall got his PhD in genetics from George Washington University, and has dedicated much of his career to cancer research and treatment. Prior to founding Seattle Genetics, he served at the National Cancer Institute as part of their research team. He also has been on the boards at Bristol-Myers Squibb, Alder BioPharmaceuticals, Mirna Therapeutics, and the Board of Governors of the Fred Hutchinson Cancer Research Business Alliance. He helped found Seattle Genetics in 1998, and has raised over $300 million in capital funds throughout his time as CEO. He’s also entered into a distribution partnership with Takada Pharmaceuticals to market his products outside the US and Canada.
Siegall’s company has manufactured and tested antibody-drug conjugates (ADCs) and Adcetris is their highest-selling product. ADCs are a special kind of antibody used for targeting tumors and cancerous cells associated with lymphomas such as Hodgkin’s. Siegall has also entered into agreements with Genentech over the use and distribution of SGN-40.